Workplace absenteeism during the high-severity 2017 to 2018 influenza season increased sharply in November and peaked in January.
According to results from the MINISTONE-2 trial, baloxavir marboxil (Xofluza) was found to be safe and effective in children 1 to less than 12 years old with an influenza infection.
Observations of 2 hygiene protocols undertaken by hospital staff found that the “Masks Save Lives” campaign is highly effective in preventing nosocomial influenza infection in clinical settings, according to data presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019 in San Francisco, California. In 2018, the “Masks Save Lives” campaign…
Season was of moderate severity and lasted 21 weeks; illness mainly attributed to influenza A viruses
There were 125 reports of 192 patients receiving expired injectable inactivated influenza vaccines during the last flu season.
Whole-genome sequencing was better at identifying nosocomial influenza A outbreak clusters than hemagglutinin (HA)/neuraminidase (NA) gene sequencing.
A significant number of asymptomatic people shed the influenza virus.
Data supporting the selection of the antiviral conjugate CB-012 as Cidara Therapeutics Incorporated’s first clinical development candidate from the company’s influenza program.
Most hold inaccurate beliefs about flu, flu shots, including believing child will be protected with one shot
October may be the best time for elderly patients to receive influenza vaccinations.
In children aged 6–35 months, vaccination with 2 doses of IIV4 can protect against influenza and reduces the frequency of severe outcomes.
Based on current data, AAP Board of Directors says either injection or nasal spray vaccination OK
Milder strain of flu has been most common cause of cases this flu season
Adults who received the flu vaccine in 2017 to 2018 had higher antibody titers against the egg-adapted vaccine and lower titers against circulating virus.
Oseltamivir should be administered to treat critically ill individuals with influenza, particularly when A/H3N2 is circulating.
The Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil; Genentech) for the treatment of influenza in patients at high risk of complications.
Postvaccination antibody titers against influenza A similar across successive vaccinations but efficacy wanes with vaccine rates.
Influenza vaccine efficacy, between November 23, 2018 and February 2, 2019, was 47% overall and 61% for young children.
An influenza vaccine cannot cause a pregnant woman to miscarry.
The current available influenza vaccine may have prevented substantial cases of influenza-associated adverse outcomes.